CRYO CELL INTERNATIONAL INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CRYO CELL INTERNATIONAL INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Nov 30, 2017 | $25.38M | Feb 28, 2018 |
| FY2017 | Nov 30, 2016 | $23.13M | Feb 28, 2018 |
| FY2016 | Nov 30, 2015 | $21.09M | Feb 28, 2017 |
| FY2015 | Nov 30, 2014 | $20.13M | Feb 29, 2016 |
| FY2014 | Nov 30, 2013 | $18.99M | Mar 2, 2015 |
| FY2013 | Nov 30, 2012 | $17.97M | Feb 28, 2014 |
| FY2012 | Nov 30, 2011 | $17.92M | Feb 28, 2013 |
| FY2011 | Nov 30, 2010 | $17.76M | Feb 28, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | ($2.43M) | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | $402.1K | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | ($9.52M) | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | $2.77M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $2.08M | Feb 28, 2023 |
| FY2021 | Nov 30, 2020 | $3.62M | Feb 22, 2022 |
| FY2020 | Nov 30, 2019 | $2.29M | Mar 1, 2021 |
| FY2019 | Nov 30, 2018 | ($854.8K) | Feb 28, 2020 |
| FY2018 | Nov 30, 2017 | $2.32M | Feb 28, 2019 |
| FY2017 | Nov 30, 2016 | ($1.32M) | Feb 28, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $482.4K | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | $3.48M | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | ($12.30M) | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | $4.02M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $4.02M | Feb 28, 2023 |
| FY2021 | Nov 30, 2020 | $7.66M | Feb 22, 2022 |
| FY2020 | Nov 30, 2019 | $5.06M | Mar 1, 2021 |
| FY2019 | Nov 30, 2018 | $5.19M | Feb 28, 2020 |
| FY2018 | Nov 30, 2017 | $5.01M | Feb 28, 2019 |
| FY2017 | Nov 30, 2016 | $433.6K | Feb 28, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $376.3K | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | $1.24M | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | $1.17M | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | $384.8K | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $49.9K | Feb 28, 2023 |
| FY2021 | Nov 30, 2020 | $23.9K | Feb 22, 2022 |
| FY2020 | Nov 30, 2019 | $30.1K | Mar 1, 2021 |
| FY2019 | Nov 30, 2018 | $91.8K | Feb 28, 2020 |
| FY2018 | Nov 30, 2017 | $41.2K | Feb 28, 2019 |
| FY2017 | Nov 30, 2016 | $53.1K | Feb 28, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $18.22M | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | $18.52M | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | $17.17M | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | $15.58M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $14.61M | Feb 28, 2023 |
| FY2021 | Nov 30, 2020 | $14.29M | Feb 22, 2022 |
| FY2020 | Nov 30, 2019 | $14.89M | Mar 1, 2021 |
| FY2019 | Nov 30, 2018 | $15.63M | Feb 28, 2020 |
| FY2018 | Nov 30, 2017 | $13.48M | Feb 28, 2019 |
| FY2017 | Nov 30, 2016 | $14.72M | Feb 28, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $5.48M | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | $6.01M | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | $8.92M | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | $8.57M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $7.93M | Feb 28, 2023 |
| FY2021 | Nov 30, 2020 | $8.47M | Feb 22, 2022 |
| FY2020 | Nov 30, 2019 | $6.29M | Mar 1, 2021 |
| FY2019 | Nov 30, 2018 | $5.33M | Feb 28, 2020 |
| FY2018 | Nov 30, 2017 | $5.72M | Feb 28, 2019 |
| FY2013 | Nov 30, 2013 | $822.0K | Feb 28, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $230.5K | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | $2.40M | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | $6.84M | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | $12.17M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $1.83M | Feb 28, 2023 |
| FY2021 | Nov 30, 2020 | $100.0K | Feb 22, 2022 |
| FY2020 | Nov 30, 2019 | $662.3K | Mar 1, 2021 |
| FY2019 | Nov 30, 2018 | $446.2K | Feb 28, 2020 |
| FY2018 | Nov 30, 2017 | $98.3K | Feb 28, 2019 |
| FY2017 | Nov 30, 2016 | $343.0K | Feb 28, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $61.73M | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | $64.68M | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | $61.22M | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | $64.89M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $60.66M | Feb 28, 2023 |
| FY2021 | Nov 30, 2020 | $46.20M | Feb 22, 2022 |
| FY2020 | Nov 30, 2019 | $42.89M | Mar 1, 2021 |
| FY2019 | Nov 30, 2018 | $42.39M | Feb 28, 2020 |
| FY2018 | Nov 30, 2017 | $23.91M | Feb 28, 2019 |
| FY2017 | Nov 30, 2016 | $19.54M | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $80.33M | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | $77.89M | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | $72.25M | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | $66.41M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $56.48M | Feb 28, 2023 |
| FY2021 | Nov 30, 2020 | $48.87M | Feb 22, 2022 |
| FY2020 | Nov 30, 2019 | $49.84M | Mar 1, 2021 |
| FY2019 | Nov 30, 2018 | $51.30M | Feb 28, 2020 |
| FY2018 | Nov 30, 2017 | $36.41M | Feb 28, 2019 |
| FY2017 | Nov 30, 2016 | $34.95M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | ($18.61M) | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | ($13.22M) | Feb 27, 2026 |
| FY2025 | Nov 30, 2023 | ($11.03M) | Feb 27, 2026 |
| FY2024 | Nov 30, 2022 | ($1.52M) | Feb 28, 2025 |
| FY2023 | Nov 30, 2021 | $4.18M | Feb 28, 2024 |
| FY2022 | Nov 30, 2020 | ($2.67M) | Feb 28, 2023 |
| FY2021 | Nov 30, 2019 | ($6.95M) | Feb 22, 2022 |
| FY2020 | Nov 30, 2018 | ($8.91M) | Mar 1, 2021 |
| FY2019 | Nov 30, 2017 | ($12.50M) | Feb 28, 2020 |
| FY2018 | Nov 30, 2016 | ($15.41M) | Feb 28, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $1.94M | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | $1.94M | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | $1.94M | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | $1.94M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $1.94M | Feb 28, 2023 |
| FY2021 | Nov 30, 2020 | $1.94M | Feb 22, 2022 |
| FY2020 | Nov 30, 2019 | $1.94M | Mar 1, 2021 |
| FY2019 | Nov 30, 2018 | $1.94M | Feb 28, 2020 |
| FY2018 | Nov 30, 2017 | $0 | Feb 28, 2019 |
| FY2017 | Nov 30, 2016 | $0 | Feb 28, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | ($38.44M) | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | ($32.78M) | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | ($31.16M) | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | ($21.64M) | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | ($16.74M) | Feb 28, 2023 |
| FY2021 | Nov 30, 2020 | ($18.82M) | Feb 22, 2022 |
| FY2020 | Nov 30, 2019 | ($22.44M) | Mar 1, 2021 |
| FY2019 | Nov 30, 2018 | ($25.33M) | Feb 28, 2020 |
| FY2018 | Nov 30, 2017 | ($24.47M) | Feb 28, 2019 |
| FY2017 | Nov 30, 2016 | ($26.79M) | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $319.0K | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | $561.0K | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | $406.1K | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | $1.70M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $8.26M | Feb 28, 2023 |
| FY2021 | Nov 30, 2020 | $10.36M | Feb 22, 2022 |
| FY2021 | Nov 30, 2019 | $6.54M | Feb 22, 2022 |
| FY2020 | Nov 30, 2018 | $6.04M | Mar 1, 2021 |
| FY2019 | Nov 30, 2017 | $6.28M | Feb 28, 2020 |
| FY2018 | Nov 30, 2016 | $3.50M | Feb 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $8.35M | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | $8.48M | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | $8.60M | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | $8.73M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $1.90M | Feb 28, 2023 |
| FY2021 | Nov 30, 2020 | $5.94M | Feb 22, 2022 |
| FY2020 | Nov 30, 2019 | $8.96M | Mar 1, 2021 |
| FY2019 | Nov 30, 2018 | $12.94M | Feb 28, 2020 |
| FY2018 | Nov 30, 2017 | $7.30M | Feb 28, 2019 |
| FY2017 | Nov 30, 2016 | $9.82M | Feb 28, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | 0 | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | (1) | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | 0 | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | 0 | Feb 28, 2023 |
| FY2021 | Nov 30, 2020 | 0 | Feb 22, 2022 |
| FY2020 | Nov 30, 2019 | 0 | Mar 1, 2021 |
| FY2019 | Nov 30, 2018 | 0 | Feb 28, 2020 |
| FY2018 | Nov 30, 2017 | 0 | Feb 28, 2019 |
| FY2017 | Nov 30, 2016 | 0 | Feb 28, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | 0 | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | (1) | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | 0 | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | 0 | Feb 28, 2023 |
| FY2021 | Nov 30, 2020 | 0 | Feb 22, 2022 |
| FY2020 | Nov 30, 2019 | 0 | Mar 1, 2021 |
| FY2019 | Nov 30, 2018 | 0 | Feb 28, 2020 |
| FY2018 | Nov 30, 2017 | 0 | Feb 28, 2019 |
| FY2017 | Nov 30, 2016 | 0 | Feb 28, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | 8.06M | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | 8.08M | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | 8.29M | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | 8.50M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | 8.55M | Feb 28, 2023 |
| FY2021 | Nov 30, 2020 | 7.55M | Feb 22, 2022 |
| FY2020 | Nov 30, 2019 | 7.51M | Mar 1, 2021 |
| FY2019 | Nov 30, 2018 | 7.80M | Feb 28, 2020 |
| FY2018 | Nov 30, 2017 | 7.10M | Feb 28, 2019 |
| FY2017 | Nov 30, 2016 | 6.79M | Feb 28, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $3.23M | Feb 27, 2026 |
| FY2025 | Nov 30, 2024 | $2.02M | Feb 27, 2026 |
| FY2024 | Nov 30, 2023 | $0 | Feb 28, 2025 |
| FY2023 | Nov 30, 2022 | $7.67M | Feb 28, 2024 |
| FY2022 | Nov 30, 2021 | $0 | Feb 28, 2023 |